ArticleScientific reports2016
Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Molecular Regulation of Virulence and Dental Biofilm Formation in Streptococcus mutans: Unravelling the Crosstalk Between the VicRK and LiaSR Two-Component Systems.Molecular oral microbiology · 2026Review
- The crosstalk between acute hepatopancreatic necrosis disease (AHPND) and the Vibrio quorum sensing (QS) system: A review.PLoS pathogens · 2026Review
- Article
- Targeting bacterial transcription factors for infection control: opportunities and challenges.Transcription · 2025Review
- Fabrication and evaluation of ribavirin-loaded electrospun nanofibers as an antimicrobial wound dressing.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Structural Insights into Regulation of Vibrio Virulence Gene Networks.Advances in experimental medicine and biology · 2023Article
- Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.International journal of molecular sciences · 2022Article
- Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA.Applied microbiology and biotechnology · 2022Article
- PsrA is a novel regulator contributes to antibiotic synthesis, bacterial virulence, cell motility and extracellular polysaccharides production in Serratia marcescens.Nucleic acids research · 2022Article
- 5-Fluorouracil blocks quorum-sensing of biofilm-embedded methicillin-resistant Staphylococcus aureus in mice.Nucleic acids research · 2021Article
- Transcriptional Regulation of the Multiple Resistance Mechanisms inPathogens (Basel, Switzerland) · 2021Review
- Deciphering the possible role of ctxB7 allele on higher production of cholera toxin by Haitian variant Vibrio cholerae O1.PLoS neglected tropical diseases · 2020Article
- Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2.Computational and structural biotechnology journal · 2020Review
- Overproduction and purification of highly active recombinant Pseudomonas aeruginosa str. PAO1 RNA polymerase holoenzyme complex.Protein expression and purification · 2019Article
- A high-throughput system to identify inhibitors ofProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Cholera: an overview with reference to the Yemen epidemic.Frontiers of medicine · 2019Review
- Approaches to the Structure-Based Design of Antivirulence Drugs: Therapeutics for the Post-Antibiotic Era.Molecules (Basel, Switzerland) · 2019Review
- Functional Annotation of Bacterial Signal Transduction Systems: Progress and Challenges.International journal of molecular sciences · 2018Review
- Regulation of the aceI multidrug efflux pump gene in Acinetobacter baumannii.The Journal of antimicrobial chemotherapy · 2018Article
- Acinetobacter: an emerging pathogen with a versatile secretome.Emerging microbes & infections · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting bacterial virulence mechanisms without compromising bacterial growth is a promising strategy to prevent drug resistance. LysR-type transcriptional regulators (LTTRs) possess structural conservation across bacterial species and regulate virulence in numerous pathogens, making them attractive targets for antimicrobial agents. We targeted AphB, a Vibrio cholerae LTTR, which regulates the expression of genes encoding cholera toxin and toxin-co-regulated pilus for inhibitor designing. Since AphB ligand is unknown, we followed a molecular fragment-based approach for ligand designing using FDA-approved drugs and subsequent screen to identify molecules that exhibited high-affinity binding to AphB ligand-binding pocket. Among the identified compounds, ribavirin, an anti-viral drug, antagonized AphB functions. Ribavirin perturbed Vibrio cholerae pathogenesis in animal models. The inhibitory effects of the drug was limited to the bacteria expressing wild type AphB, but not its constitutively active mutant (AphB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.